Skip to content
VOR·Nasdaq·US

Vor Biopharma

Vor Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel therapy for autoimmune diseases, having in-licensed telitacicept from RemeGen Co., Ltd. in June 2025 to develop and commercialize it outside Greater China. Telitacicept is approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis, and the company is conducting global Phase 3 clinical trials to support potential regulatory approval in the United States, Europe, and Japan.

Source: SEC 10-K Mar 30, 2026

Thematic Position

VOR

Relationship Groups

Suppliers1
Licensing3
Competitors27

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government rightsmarch-in rightsintellectual property regulation
Bayh-Dole Act grants U.S. government march-in rights over federally funded inventions
SEC 10-KMar 30, 2026

The full regulatory passage is part of the Pro plan.

6 more · Regulatory and geopolitical insights are part of the Pro plan.